Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 8/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13033775 | 0.97 | SMO (0.46) | SMOGPR119UCHL1NR1H2NR1H3 | |
| SCHEMBL13033820 | 0.95 | UCHL1 (0.47) | SMOGPR119UCHL1OPRM1OPRD1 | |
| SCHEMBL13033825 | 0.95 | UCHL1 (0.47) | SMOGPR119UCHL1OPRM1OPRD1 | |
| SCHEMBL13033738 | 0.94 | SMO (0.47) | SMOGPR119UCHL1OPRM1OPRD1 | |
| SCHEMBL13033726 | 0.94 | SMO (0.47) | SMOGPR119UCHL1OPRM1OPRD1 | |
| SCHEMBL13033822 | 0.93 | SMO (0.46) | SMOGPR119UCHL1VCP | |
| SCHEMBL13033827 | 0.93 | SMO (0.46) | SMOGPR119UCHL1VCP | |
| SCHEMBL13033740 | 0.92 | SMO (0.47) | SMOGPR119UCHL1VCPOPRM1 | |
| SCHEMBL13033728 | 0.92 | SMO (0.47) | SMOGPR119UCHL1VCPOPRM1 | |
| SCHEMBL3511102 | 0.90 | SMO (0.48) | SMOGPR119NR1H2NR1H3VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | SMO 3/4885GPR119 151/4885UCHL1 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.